sanofi-aventis Canada Inc. (Sanofi Canada) is pleased to announce that Health Canada has issued a Notice of Compliance ("NOC") for Rezurock™ (belumosudil tablets), for the treatment of adult and...

The certification recognizes the outstanding commitments and actions of companies to achieve gender parity at all levels of business. Sanofi has committed to reaching gender parity amongst the...

Nirsevimab is the first investigational long-acting antibody designed for all infants to help protect against respiratory syncytial virus (RSV) throughout their first RSV season with a single dose...